(UroToday.com) The American Urological Association's 2025 Annual Meeting, between April 26 – 29, 2025 in Las Vegas, Nevada, was host to the Society of Urologic Oncology (SUO) Session. Dr. Bernard ...

Oncologists at AUA 2025 share promising data, including sasanlimab, cretostimogene grenadenorepvec, and TAR-200 in NMIBC.

With an FDA review underway, Johnson & Johnson is aiming to “fundamentally change” how bladder cancer is treated. | With an ...

The positive predictive value (PPV) for Bladder EpiCheck was 67.4%, with a negative predictive value (NPV) for both overall and HG disease of 99.6%. WLC demonstrated a PPV of 74%, an NPV of 96.3%, and ...

Johnson & Johnson (JNJ) posts promising Phase 2b trial results for its chemotherapy releasing system TAR-200 in bladder ...

Bacillus Calmette-Guérin (BCG) remains the primary treatment for patients with high-risk bladder cancer, but resistance develops in 30% to 40% of cases. The use of oncolytic viruses has emerged as a ...

UroGen Pharma's potential remains strong despite market volatility, with promising FDA prospects for UGN-102 & a $5B ...

The first targeted treatment for the most common form of bladder cancer has been given the green light for NHS use. The recommendation on erdafitinib by the National Institute of Health and Care ...

A groundbreaking targeted treatment for the most common type of bladder cancer has been approved for use by the NHS, offering new hope to hundreds of patients. The National Institute of Health and ...